Information  X 
Enter a valid email address

Synairgen PLC Ord 1P (SNG)

Date Time Source Announcement
19 Nov 2021 2:26 pm
RNS
Holding(s) in Company
11 Nov 2021 7:00 am
RNS
Synairgen completes Phase III recruitment
08 Nov 2021 12:58 pm
RNS
Holding(s) in Company
26 Oct 2021 3:13 pm
RNS
Holding(s) in Company
21 Oct 2021 5:39 pm
RNS
Holdings in Company
  7:00 am
RNS
Grant of Options
20 Oct 2021 7:00 am
RNS
SNG001 progresses to Phase 3 of ACTIV-2 trial
13 Oct 2021 7:00 am
RNS
Synairgen appoints Gareth Walters, Ph.D. as CRO
05 Oct 2021 11:25 am
RNS
Holding(s) in Company
30 Sep 2021 7:02 am
RNS
Non-Executive Director Appointment
  7:02 am
GNW
Non-Executive Director Appointment
  7:01 am
GNW
Interim results for the six months ended 30 June 2021
  7:00 am
RNS
Interim results
21 Sep 2021 7:00 am
RNS
Synairgen Notice of Interim Results
10 Sep 2021 11:30 am
RNS
Holding(s) in Company
12 Aug 2021 4:12 pm
RNS
Exercise of Options and Total Voting Rights
06 Aug 2021 12:21 pm
RNS
Holding(s) in Company
29 Jun 2021 4:28 pm
RNS
Holding(s) in Company
18 Jun 2021 10:29 am
RNS
Result of AGM
07 Jun 2021 7:00 am
RNS
Grant of Options
25 May 2021 4:28 pm
RNS
Notice of AGM
24 May 2021 7:00 am
RNS
Results of in vitro studies
  7:00 am
GNW
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
12 May 2021 7:00 am
RNS
Full Year Results
  7:00 am
GNW
Preliminary results for the year ended 31 December 2020
30 Apr 2021 7:00 am
RNS
Home Cohort data of SG016 Phase II trial
  7:00 am
GNW
Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial
16 Apr 2021 4:37 pm
RNS
Holding(s) in Company
15 Apr 2021 11:44 am
RNS
Holding(s) in Company
06 Apr 2021 4:36 pm
RNS
Holding(s) in Company
15 Feb 2021 7:00 am
RNS
Dosing commenced in US ACTIV-2 trial
  7:00 am
GNW
Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
25 Jan 2021 7:00 am
RNS
Inclusion in US ACTIV-2 trial
  7:00 am
GNW
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
20 Jan 2021 7:00 am
RNS
Home trial recruitment completed
  7:00 am
GNW
Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta
13 Jan 2021 7:00 am
RNS
First Patient Dosing in Phase III SG018 Trial
  7:00 am
GNW
Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
06 Jan 2021 5:10 pm
RNS
Holding(s) in Company
05 Jan 2021 5:53 pm
RNS
Holding(s) in Company
18 Dec 2020 7:00 am
RNS
COVID-19 Clinical Programme Update
  7:00 am
GNW
COVID-19 Clinical Programme Update
10 Dec 2020 12:57 pm
RNS
Holding(s) in Company
13 Nov 2020 5:03 pm
RNS
Holding(s) in Company
  7:00 am
RNS
Lancet Respiratory Medicine publishes Phase 2 data
10 Nov 2020 1:47 pm
RNS
Holding(s) in Company
04 Nov 2020 5:51 pm
RNS
Holding(s) in Company
03 Nov 2020 9:00 am
RNS
Holding(s) in Company
02 Nov 2020 12:20 pm
RNS
Result of General Meeting and Total Voting Rights
  7:00 am
RNS
Result of Open Offer
28 Oct 2020 11:20 am
RNS
Holding(s) in Company
27 Oct 2020 8:35 am
RNS
Holding(s) in Company
21 Oct 2020 9:45 am
RNS
Holding(s) in Company
  9:40 am
RNS
Holding(s) in Company
16 Oct 2020 3:10 pm
RNS
Exercise of Options and Total Voting Rights
15 Oct 2020 5:35 pm
RNS
Exercise of Options and Total Voting Rights
  1:51 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Results of Placing
14 Oct 2020 5:32 pm
RNS
Placing and Open Offer
12 Oct 2020 11:05 am
RNS
Second Price Monitoring Extn

a d v e r t i s e m e n t